Floatz logo

Busulphan

Multiple Sclerosis, Primary Progressive

Stanford UniversityPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Multiple Sclerosis, Primary Progressive cohort.

Asset / SponsorPhaseRating
Fampridine
University College Dublin
Phase 4BBB
Masitinib
AB Science
Phase 3B
Kyv-101
Kyverna Therapeutics
Phase 2B
Fenebrutinib
Hoffmann-La Roche
Phase 3B
Ibudilast
MediciNova
Phase 2B

View all 16 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →